Angiotensin-converting enzyme inhibitors (ACEIs) have traditionally been considered the primary treatment for reducing mortality after acute myocardial infarction (MI), preventing the development of heart failure, and potentially preventing subsequent MIs [5]. Here, ACE is linked to myocardial infarction.